Paclitaxel-Coated Peripheral Arterial Devices are Associated with Reduced Mortality in Younger Patients
| Autor: | Ravi N. Ambani, Karem C. Harth, Benjamin Colvard, Saideep Bose, Alexander H. King, Jae S. Cho, Jones P. Thomas, Vikram S. Kashyap, Virginia L. Wong, Norman H. Kumins |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
medicine.medical_specialty Atherectomy Time Factors Percutaneous Paclitaxel medicine.medical_treatment 030204 cardiovascular system & hematology Risk Assessment 030218 nuclear medicine & medical imaging Peripheral Arterial Disease 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Restenosis Risk Factors Angioplasty Internal medicine medicine Humans Popliteal Artery Aged Retrospective Studies Aged 80 and over business.industry Age Factors Cardiovascular Agents Drug-Eluting Stents Retrospective cohort study General Medicine Middle Aged medicine.disease Femoral Artery Treatment Outcome chemistry Cohort Female Surgery Cardiology and Cardiovascular Medicine Risk assessment business Angioplasty Balloon |
| Zdroj: | Annals of Vascular Surgery. 70:70-78 |
| ISSN: | 0890-5096 |
| DOI: | 10.1016/j.avsg.2020.08.003 |
| Popis: | Paclitaxel-coated devices have been shown to decrease restenosis when used in the femoropopliteal artery. Recent reports have suggested a possible risk of increased late mortality in patients treated with paclitaxel. It has been suggested that younger patients and those with limited comorbidities may be at higher risk. Our objective was to analyze long-term mortality based on patient age comparing treatment with paclitaxel to uncoated devices.We performed a retrospective review of 1,170 consecutive patients who underwent femoropopliteal percutaneous intervention by angioplasty, atherectomy, stent placement, or combination between 2011 and 2018. Patients were grouped by age at the time of procedure:60 years old (n = 244, 20.9%), 60-80 years old (n = 635, 54.3%), and80 years old (n = 291, 24.9%). Within each group, patients were further divided by use of paclitaxel. The primary outcome measure was survival assessed by Kaplan-Meier analysis. Differences between the groups were analyzed with analysis of variance. Multivariable analysis was performed using Cox proportional hazard models.Of the 1,170 patients who underwent femoropopliteal percutaneous intervention, 654 (55.9%) received a paclitaxel-coated device during treatment and 516 (44.1%) did not. Mean age of the overall patient cohort was 70.4 ± 12.6 years and 663 (56.7%) were male. When comparing the groups by age we found an increase in age but a decrease in the proportion of patients who smoke. The use of paclitaxel-coated devices was similar across the groups (60 years old, 56.2%; 60-80 years old, 57.0%;80 years old, 52.6%; P = 0.45). Demographics and comorbidities were similar between the patients treated with and without paclitaxel within each age group except more males in the60-year-old group treated without paclitaxel and more patients with chronic limb threatening ischemia in the80-year-old group treated with paclitaxel. In patients60 and 60-80 years old paclitaxel use was associated with increased survival at 4 years:60 (80.7% vs. 64.4%; P = 0.04); 60-80 (63.2% vs. 55.1%; P = 0.04). Survival was similar in the80-year-old group (46.6% vs. 32.8%; P = 0.65).Our data suggest that the use of paclitaxel-coated arterial devices is not associated with increased mortality. On the contrary, our data show that younger patients treated with paclitaxel show improved survival compared with those treated without paclitaxel. Paclitaxel-coated devices may be used with continued caution especially in patients at high risk for restenosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|